FDA’s cell and gene therapy head steps down after 1 year
Vijay Kumar, acting director of CBER’s Office of Therapeutic Products, will leave his role at a tumultuous time for the FDA.
FDA’s cell and gene therapy head steps down after 1 year Read More »
